Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Molecular Imaging of Proliferation in Malignant Lymphoma

Open access
Buck, Andreas K., Bommer, Martin, Stilgenbauer, Stephan, Juweid, Malik, Glatting, Gerhard, Schirrmeister, Holger, Mattfeldt, Torsten, Tepsic, Djurdja, Bunjes, Donald, Mottaghy, Felix M., Krause, Bernd J., Neumaier, Bernd, Döhner, Hartmut, Möller, Peter, Reske, Sven N. · 2006 · Cancer Research

Abstract

We have determined the ability of positron emission tomography (PET) with the thymidine analogue 3′-deoxy-3′-[18F]fluorothymidine (FLT) to detect manifestation sites of malignant lymphoma, to assess proliferative activity, and to differentiate aggressive from indolent tumors. In this prospective study, FLT-PET was done additionally to routine staging procedures in 34 patients with malignant lymphoma. Sixty minutes after i.v. injection of ∼330 MBq FLT, emission and transmission scanning was done. Tracer uptake in lymphoma was evaluated semiquantitatively by calculation of standardized uptake values (SUV) and correlated to tumor grading and proliferation fraction as determined by Ki-67 immunohistochemistry. FLT-PET detected a total of 490 lesions compared with 420 lesions revealed by routine staging. In 11 patients with indolent lymphoma, mean FLT-SUV in biopsied lesions was 2.3 (range, 1.2-4.5). In 21 patients with aggressive lymphoma, a significantly higher FLT uptake was observed (mean FLT-SUV, 5.9; range, 3.2-9.2; P < 0.0001) and a cutoff value of SUV = 3 accurately discriminated between indolent and aggressive lymphoma. Linear regression analysis indicated significant correlation of FLT uptake in biopsied lesions and proliferation fraction (r = 0.84; P < 0.0001). In this clinical study, FLT-PET was suitable for imaging malignant lymphoma and noninvasive assessment of tumor grading. Due to specific imaging of proliferation, FLT may be a superior PET tracer for detection of malignant lymphoma in organs with high physiologic fluorodeoxyglucose uptake and early detection of progression to a more aggressive histology or potential transformation. (Cancer Res 2006; 66(22): 11055-61)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-1955

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 185

Metadata

Authors
Buck, A. K., Bommer, M., Stilgenbauer, S., Juweid, M., Glatting, G., Schirrmeister, H., Mattfeldt, T., Tepsic, D., Bunjes, D., Mottaghy, F. M., Krause, B. J., Neumaier, B., Döhner, H., Möller, P., & Reske, S. N.
Venue
Cancer Research
Published
2006-11-15
Volume
66
Issue
22
Pages
11055-11061
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2001468757
Cited by
185
References
1
FWCI
9.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Imaging of Proliferation in Malignant Lymphoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1955
The paper
Buck, A. K., Bommer, M., Stilgenbauer, S., Juweid, M., Glatting, G., Schirrmeister, H., Mattfeldt, T., Tepsic, D., Bunjes, D., Mottaghy, F. M., Krause, B. J., Neumaier, B., Döhner, H., Möller, P., & Reske, S. N. (2006). Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.